A Phase 3, Modified-double Blind, Multi-center Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers (2 to 23 Months of Age) in China

The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China.
Study details include:
* Study duration (including 6-month safety follow-up after the last dose): - Cohort I (Groups 1 and 2): approximately 211 or 271 days (approximately 7 or 9 months) - Cohort II (Groups 3 and 4): up to 18 months - Cohort III (Groups 5 and 6): up to 21 months - Cohort III (Group 7): approximately 16 months
* Vaccination Visits Period:
* Cohort I (Groups 1 and 2): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121). Telephone calls (TCs) are planned on the 4th, the 9th, and the 21st day after each vaccination, and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit for safety follow-up. For participants receiving the second vaccination with a 3-month interval: an on-site visit is planned 30 days post the 1st dose of vaccination (V02, D31) for participant diary collection.
* Cohort II (Groups 3 and 4): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). A 1-dose booster is planned for Group 3 only at 18 MoA (within the 18th month from the participant's birth date). Up to 4 blood samples will be collected. In the primary vaccination period, blood samples are collected before the first primary vaccination (D01) and 30 days post the 2nd dose of primary vaccination (D61 or D121). A blood sample will be collected from all participants at 18 MoA. A post-booster blood sample will be collected from participants in Group 3, 30 days post their booster vaccination. Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods, respectively, for safety follow-up. For participants receiving the second vaccination with a 3-month interval: an on-site visit is planned 30 days post the 1st dose of vaccination (V02, D31) for participant diary collection. - Cohort III - Groups 5 and 6: a 3-dose primary vaccination at V01 (D01), V02 (D31) and V03 (D61), a 1-dose booster at 12 MoA (within the 12th months from the participant's birth date) on V05 or at 18 MoA (within the 18th months from the participant's birth date) on V06.
In total 4 blood samples are to be collected. In the primary vaccination period, blood samples are to be collected before the first primary vaccination (D01) and 30 days post the 3rd dose of primary vaccination (D91); in the booster vaccination period, blood samples are to be collected before booster vaccination at V05 (for participants receiving the booster at 12 MoA) or V06 (for participants receiving the booster at 18 MoA), and 30 days post booster vaccination (V05 + 30 days or V06 + 30 days). Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods respectively for safety follow-up.
- Cohort III - Group 7: a 3-dose primary vaccination at V01 (D01), V02 (D61) and V03 (D121), a 1-dose booster at V05 at 12 MoA (within the 12th months from the participant's birth date).
In total 4 blood samples are to be collected. In the primary vaccination period, blood samples are to be collected before the first primary vaccination (D01) and 30 days post the 3rd dose of primary vaccination (D151); in the booster vaccination period, blood samples are to be collected before booster vaccination at V05 and 30 days post booster vaccination (V06). Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods (ie, V04 and V06), respectively, for safety follow-up. A safety visit is planned on the 9th day after the first vaccination for the ESDR participants (the first 30 participants in this group).

开始日期2026-08-20

申办/合作机构

Sanofi

NCT07621653

/ Not yet recruitingN/A

Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea

This surveillance is to investigate the safety profile of MenQuadfi®, when administered to participants aged 6 weeks to 55 years under the real-world clinical practice settings as per approved indications, including the Adverse Drug Reactions (ADRs)*.
*It includes ADRs that were not fully recognized in clinical practice, or unexpected ADRs which refer to those not listed in the approved drug labeling.

开始日期2026-05-27

申办/合作机构

Sanofi

NCT07135986

/ Active, not recruiting临床3期

A Phase 3, Modified Double-blind, Multi-center Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents (2 to 17 Years of Age) in China

This is a Phase 3, modified double-blind, randomized, parallel-group, active-controlled, multicenter study with 2 arms and 4 groups to evaluate the immunogenicity and safety of MenACYW conjugate vaccine in children and adolescents versus control meningococcal vaccines licensed in China.
Study details include:
* The study duration will be approximately 180 days.
* The vaccination visit will be Visit 1.
* The visit frequency will be 2 on-site visits with a 30-day interval. A safety visit/telephone call is planned on the ninth day after the vaccination for all groups; a safety follow-up telephone call is planned for all groups 180 days post the last vaccination.

开始日期2025-09-26

申办/合作机构

Sanofi

100 项与 ACYW135群脑膜炎球菌结合疫苗(赛诺菲) 相关的临床结果

登录后查看更多信息

100 项与 ACYW135群脑膜炎球菌结合疫苗(赛诺菲) 相关的转化医学

登录后查看更多信息

100 项与 ACYW135群脑膜炎球菌结合疫苗(赛诺菲) 相关的专利（医药）

登录后查看更多信息

项与 ACYW135群脑膜炎球菌结合疫苗(赛诺菲) 相关的文献（医药）

2026-12-31·Human Vaccines & Immunotherapeutics

Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study

Article

作者: Lechevin, Isabelle ; Atwi, Jibran ; Prato, Rosa ; Keshavan, Pavitra ; Moraschini, Luca ; Hoberman, Alejandro ; Possidente, Mariapia ; Lattanzi, Maria ; Silas, Peter ; Martin, Judith M. ; Bosis, Samantha ; Manzella, Sara

Meningococcal vaccination of adolescents/young adults is recommended in various countries, including the United States (US). This phase 3b, observer-blind study (NCT04318548) evaluated the safety, reactogenicity, and immunogenicity of serogroup B vaccine, 4CMenB, and quadrivalent conjugate vaccine, MenACWY-CRM, when co-administered to healthy individuals aged 16-18 y, as per US Advisory Committee on Immunization Practices recommendations. Adolescents, who had received MenACWY vaccination ≥4 y previously, were randomized (N = 940; 1:1:1) to one of three groups to assess co-administration versus 4CMenB and MenACWY-CRM administered alone. Co-primary objectives were to demonstrate the non-inferiority of antibody responses after concomitant administration to antibody responses after 4CMenB (two doses administered 2 months apart) and MenACWY-CRM (single dose), as measured by human serum bactericidal assay (hSBA). Vaccine safety and reactogenicity were assessed as another primary objective. The co-primary endpoints were met: the lower limit of 2-sided 95% confidence intervals for all between-group ratios of hSBA geometric mean titers was >0.5 for the concomitant administration group versus 4CMenB group and MenACWY-CRM group. hSBA data after two 4CMenB doses and one MenACWY-CRM dose showed comparable between-group geometric mean ratios versus baseline, and percentages of participants with 4-fold rises in titers and titers ≥lower limit of quantitation. The safety profile of 4CMenB co-administered with MenACWY-CRM was comparable with that of 4CMenB administered alone. In conclusion, 4CMenB and MenACWY-CRM co-administration was well tolerated in adolescents aged 16-18 y and immune responses were comparable versus administration of each vaccine alone, which is consistent with a previous study of co-administration in infants.

2025-12-31·Human Vaccines & Immunotherapeutics

A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT)

Review

作者: Tezer, Hasan ; Somer, Ayper ; Ciftci, Ergin ; Dinleyici, Ener Cagri ; Yilmaz, Dilek

Neisseria meningitidis (Nm) remains a major global health concern, causing invasive meningococcal disease (IMD) with significant morbidity and mortality. Despite vaccination efforts, Nm serogroup prevalence and antibiotic resistance continue to evolve, necessitating ongoing surveillance and novel immunization strategies. This review aims to assess the role of MenACWY-TT, a quadrivalent meningococcal conjugate vaccine, in IMD prevention by evaluating its immunogenicity, safety, and real-world effectiveness. The objectives include analyzing its advantages over existing vaccines, identifying gaps in long-term immunity data, and assessing its potential integration into National Immunization Programs (NIPs). MenACWY-TT has demonstrated strong immunogenicity, a favorable safety profile, and ease of administration with its liquid, non-adjuvanted formulation. Real-world studies show high vaccine effectiveness and herd protection benefits. However, further research is needed to evaluate long-term immunity and efficacy in high-risk populations.

2025-06-01·Infectious Diseases and Therapy

Correction: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study

作者: Icardi, Giancarlo ; Simkó, Róbert ; Syrkina, Olga ; Zocchetti, Céline ; Bertrand-Gerentes, Isabelle ; Chong, Chan Poh ; Díez-Domingo, Javier ; Bchir, Siham

项与 ACYW135群脑膜炎球菌结合疫苗(赛诺菲) 相关的新闻（医药）

2026-07-02

·埋汰猫哥的药生活

8款创新药密集获批两款CAR-T首进医保初审

8款创新药密集获批两款CAR-T首进国家医保初审一周获批：8款创新药（6/17-23）企业产品亮点百利天恒BL-B01D1全球首个EGFR×HER3双抗ADC 科济药业CT041全球首个实体瘤CAR-T 智翔金泰狂犬病双抗病毒中和双靶点首药控股CT-707二代ALK抑制剂麓鹏制药LP-168BTK非共价抑制剂和誉医药/海思科License-out海外授权合作 CAR-T医保突破本周两款CAR-T通过国家医保目录初审：科济药业舒瑞基奥仑赛（实体瘤）和恒润达生雷尼基奥仑赛（B细胞肿瘤）。另有3款（含精准生物普基奥仑赛）通过商保创新目录审查。产品企业路径舒瑞基奥仑赛科济药业⚕️ 基本目录初审雷尼基奥仑赛恒润达生⚕️ 基本目录初审普基奥仑赛精准生物商保创新目录审查但落地仍有难度：全国仅223家机构具备CAR-T治疗资质，三级医院覆盖率仅12.3%。目前惠民保是CAR-T的主要落地场景。赛诺菲头对头单挑曼海欣赛诺菲四价流脑结合疫苗MenQuadfi III期临床（N=4568）设计为头对头比较康希诺曼海欣——此举罕见。曼海欣2021年获批，是国内首个四价流脑结合疫苗，上市至今占据主导地位。赛诺菲直接用自家产品正面PK，表明其对国产先发优势的重视程度。市场信号：开源证券研报指出，本月创新药研发及商业化保持活跃，License-out交易持续，和誉医药、海思科、帆礼生物、德琪医药等与海外合作。国内创新药全球化加速。 — END — 免责声明：本文内容转载自腾讯新闻（每日经济新闻），版权归原作者所有。本号仅作分享交流之用，不用于任何商业用途。如涉及版权问题，请联系我们及时处理。来源：腾讯新闻（每日经济新闻）

免疫疗法细胞疗法引进/卖出疫苗临床3期

2026-06-29

·化工潘说

2026 年 6 月 22–25 日人用医药产品委员会（CHMP）会议要点

喜欢我的分享，点击上方关注我吧！ 2026 年 6 月 22–25 日人用医药产品委员会（CHMP）会议要点 2026 年 6 月人用医药产品委员会（CHMP）会议议程已发布于欧洲药品管理局（EMA）官网；本次会议纪要将于未来数周内对外公示。 2026 年 6 月统计数据 ——CHMP 审评意见及撤回申请月度、累计数据新药正面审评意见：6 份其中普通新药 3 款、罕见病药 1 款、生物类似药 2 款； 2026 年累计：42 份新药否定审评意见：3 份 2026 年累计：6 份适应症拓展正面审评意见：13 份 2026 年累计：72 份新药上市申请撤回：0 份 2026 年累计：5 份 6款新药获上市推荐许可欧洲药品管理局人用医药产品委员会（CHMP）在 2026 年 6 月会议上，推荐六款药品获批上市。委员会建议授予Aujemflu（灭活流感病毒表面抗原：血凝素 + 神经氨酸酶）上市许可，该疫苗用于 50 周岁及以上人群流感预防。 CHMP 建议授予Hopledo（左旋多巴 / 卡比多巴）上市许可，用于成人帕金森病，且经口服左旋多巴 - 多巴脱羧酶抑制剂方案治疗后病情控制不佳、伴中重度运动波动（运动功能异常）患者。 Onswik（艾夫西托阿法胰岛素）获 CHMP 正面审评意见，适应症为成人 2 型糖尿病。委员会对2款生物类似药出具支持意见： Denosumab Ascend（地舒单抗）：用于伴骨转移晚期实体瘤成人患者骨相关并发症预防；以及成人、骨骼发育成熟青少年骨巨细胞瘤治疗。 Nylaspeg（培非格司亭）：用于缩短化疗所致中性粒细胞减少症（中性粒细胞为一类白细胞）持续时间，降低发热性中性粒细胞减少症发生率。复审结果经复审后，委员会建议授予Daybu（曲非奈肽）上市许可，用于 5 周岁及以上儿童与成人雷特综合征神经行为相关症状治疗。相关神经行为症状包括手部重复刻板动作、躁动、情绪异常、焦虑、睡眠障碍及沟通障碍。 CHMP 最初曾驳回本品用于雷特综合征的上市申请；本次复审后同意批准上市，但适应症范围受限。如需了解本次复审详细结论，可查阅下方表格配套问答文件。三款药品获否定审评意见委员会对三款药品出具不予批准意见： Tacquell（自体黑色素瘤来源肿瘤浸润淋巴细胞，体外扩增）：用于晚期黑色素瘤（已发生全身转移的皮肤恶性肿瘤）。 Yartemlea（那索普利单抗）：用于 2 周岁及以上造血干细胞移植（HSCT）相关血栓性微血管病成人及儿童患者。血栓性微血管病是造血干细胞移植后可危及生命的严重并发症；造血干细胞移植指替换患者自身骨髓，植入供者干细胞重建可生成健康血细胞的骨髓。 Xervyteg（混合异体粪便微生物制剂）：用于急性移植物抗宿主病（aGvHD）。该病为移植术后高危致命病症，骨髓 / 干细胞移植后供体细胞攻击受者机体。如需了解上述三款药品不予批准的详细说明，可查阅下方表格配套问答文件。、 12 款药品获批拓展治疗适应症 CHMP 出具正面意见，建议修订Imvanex上市许可条款。本品为天花、猴痘及痘苗病毒（痘病毒科另一毒株）预防疫苗，本次建议适用人群最低年龄下调至 2 周岁及以上（原 12 周岁及以上）。委员会同时建议欧盟境内已上市的另外 11 款药品新增适应症，分别为：Datroway、Jaypirca、Leqvio、Menquadfi、Opzelura、Orladeyo、Rezolsta、Rinvoq、Stelara、Symtuza、Tecvayli。两项适应症拓展申请撤回两款复方制剂拓展适应症申请已撤回：DuoResp Spiromax、BiResp Spiromax（布地奈德 / 福莫特罗）原申请新增 “仅用于轻度哮喘急救缓解治疗” 的适应症。启动欧盟法规第 31 条集中审评程序委员会启动对利福平口服混悬液 / 糖浆（20 毫克 / 毫升）的专项审评。本品含抗生素利福平，用于结核病及其他重度感染治疗。启动审评原因是监管方担忧辅料二乙醇胺（DEA）含量存在安全隐患；啮齿动物长期高剂量暴露试验提示二乙醇胺可能具有致癌性。本次审评由荷兰药品管理局依据《欧盟指令 2001/83/EC》第 31 条提请启动，相关启动通告详见下方表格。集中审评程序收尾结论 CHMP 完成对Tavneos（阿伐可泮）的全部审评工作，建议欧盟撤销该药品上市许可，现有证据无法证实其临床获益大于用药风险。本品用于成人重度活动性肉芽肿性多血管炎（GPA）、显微镜下多血管炎（MPA），二者均为罕见血管炎症。本次专项审评启动，是因新出现信息对支撑本品欧盟获批的核心临床试验数据完整性提出重大质疑。其他更新事项 CHMP 批准Fluenz（鼻喷减毒活流感疫苗）可由非医疗专业人员在医护人员监督下完成接种。本品为鼻喷剂型，用于 2 周岁至 18 周岁以下儿童青少年季节性流感预防。委员会建议修订Ixchiq（减毒基孔肯雅疫苗）上市许可条款，限定仅适用于 12 周岁及以上、基孔肯雅病毒高感染风险人群。 CHMP 完成Mounjaro（替尔泊肽）新增适应症申请审评：原申请拓展适应症为合并心血管疾病的成人 2 型糖尿病，用于降低主要不良心血管事件（心、循环系统严重病变）风险。委员会未批准该新增适应症，但同意将申报配套研究数据纳入药品说明书，确保临床医师可查阅替尔泊肽在合并心血管疾病 2 型糖尿病人群中的完整研究数据。【关键专业术语注解】 marketing authorisation：上市许可 positive/negative opinion：正面审评意见 / 不予批准（否定）意见 biosimilar medicines：生物类似药 re-examination：上市申请复审 restricted indication：受限适应症 referral：欧盟集中专项审评程序 excipient：药用辅料 possible carcinogen：潜在致癌物 product information：药品说明书（欧盟统一称谓） febrile neutropenia：发热性中性粒细胞减少症 autologous /allogeneic：自体 / 异体 graft-versus-host disease (GvHD)：移植物抗宿主病 cardiovascular events：心血管不良事件 reliever-only treatment：仅急救缓解治疗 live nasal influenza vaccine：鼻喷减毒活流感疫苗 Agenda：会议议程 minutes：（官方）会议纪要（药监机构固定专用表述，非普通分钟）原文延伸： https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2026 内容来源于EMA,翻译仅供参考学习希望搭建一个理性交流的平台，与志同道合者共同探讨化工的未来图景。 ——专注化工领域懂您的需求—— 化工综合服务提供商企业官网建设|产品国内外推广|撮合交易|行情资讯|供应链金融业务联系：潘经理手机：13958177281(微信同号）邮箱：472097288@qq.com 加我微信，获取更多福利化工潘说——化工一起说关注我，获取更多信息！

2026-06-03

·北京医学感染与传染研究

感染性疾病与治疗 15卷 1-6期

Infectious Diseases and Therapy Volume 15, Issue 1 感染性疾病与治疗 15卷 1期 https://link.springer.com/journal/40121/volumes-and-issues/15-1 Review（综述） 1 How to Better Screen for Blood-Borne Viruses, Specifically HIV, in Hospital Emergency Departments: French and European Perspectives 医院急诊科如何更好地筛查血源性病毒（尤其是HIV）：法国和欧洲视角 Anthony Romain ChauvinBruno George SpireOlivier Bouchaud Pages: 1 - 18 2 Understanding the Epidemiology and Contributing Factors of Post-COVID-19 Pertussis Outbreaks: A Narrative Review 了解新冠疫情后百日咳爆发的流行病学及影响因素：叙述性综述 Juan C. Vargas-ZambranoSorin AbrudanDenis Macina Pages: 19 - 41 Part of 1 collection: Digital Features - Infectious Diseases 所属专题集：数字专题 - 传染病 3 The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review 康替唑胺抗结核的结构、特性及临床应用价值：叙述性综述 Tao ChenWeili LiFan Wu Pages: 43 - 56 4 A Review of Doxycycline Post-Exposure Prophylaxis and Its Implications for Antimicrobial Resistance and the Human Microbiome 综述：多西环素暴露后预防用药及其对抗菌药物耐药性和人体微生物组的影响 Ruben Fernandez-IbanezSantiago MorenoMoises Fernandez Pages: 57 - 84 Original Research（论著） 5 Clinical Impact of Implementing a Specific Clinical Pathway for the Management of Clostridioides difficile Infection 实施特定临床方法治疗艰难梭菌感染的临床影响 Miguel Rodríguez-FernándezRocio HerreroNicolás Merchante Pages: 85 - 100 6 Intensive Care Unit Stay and Mechanical Ventilation Among Adults with Respiratory Syncytial Virus-Related Hospitalization by Age and Comorbidity Status 按年龄和合并症状况划分的呼吸道合胞病毒相关住院成人患者的重症监护病房住院时间和机械通气情况 Caihua LiangYun ZhouElizabeth Begier Pages: 101 - 115 7 Treatment Persistence and Switch Among Medicare-Insured People with HIV and Gaps in Care 医疗保险覆盖的HIV感染者治疗坚持情况、用药转换情况及护理缺口 Suying LiUche MordiPhyllis C. Tien Pages: 117 - 132 8 High-Dose Minocycline Improves Outcomes in Acinetobacter baumannii Group Pneumonia: A Propensity-Weighted Cohort Study with MIC-Based Insights for Breakpoint Revision 大剂量米诺环素可改善鲍曼不动杆菌群肺炎的预后：一项基于倾向加权队列的研究，并基于最低抑菌浓度提出折点修订见解 Yu-Tao TsengYang-Chuan ChenYung-Chih Wang Pages: 133 - 148 9 Post-cranial Neurosurgery Cutibacterium acnes Infections: Clinical Correlates, Presentation, and Outcomes—A Matched Case–Case–Control Study 颅脑神经外科术后皮肤杆菌属感染：临床相关性、表现及预后——一项匹配病例-病例-对照研究 Neta ShirinOfek ArvivIli Margalit Pages: 149 - 164 10 Bone Mineral Density Changes in People with HIV Who had Immediate Switch Versus Deferred Switch from Tenofovir Disoproxil Fumarate-Based Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Multicenter, Open-Label, Randomized Clinical Trial 从基于富马酸替诺福韦二吡呋酯的方案立即转换与延迟转换为比克替拉韦/恩曲他滨/丙酚替诺福韦的HIV感染者骨密度变化：一项多中心、开放标签、随机临床试验 Yueming ShaoXinping YangJun Chen Pages: 165 - 181 11 Microbiological, Clinical, and Pharmacokinetic/Pharmacodynamic Data to Support EUCAST Aztreonam–Avibactam Minimum Inhibitory Concentration Susceptibility Breakpoints Against Enterobacterales 支持欧洲抗微生物药物敏感性试验委员会（EUCAST）针对肠杆菌科细菌的氨曲南-阿维巴坦最低抑菌浓度敏感性折点的微生物学、临床及药代动力学/药效学数据 Susan R. RaberRujia XieJoseph W. Chow Pages: 183 - 195 12 Epidemiology of Invasive Escherichia coli Disease in Adults Using Routine Healthcare Records from the United States, 2002–2022 利用美国常规医疗记录（2002-2022年）分析成人侵袭性大肠杆菌病的流行病学特征 Mark A. SchmidtMaxim BlumJeroen Geurtsen Pages: 197 - 216 13 Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies 转换为比克替拉韦/恩曲他滨/丙酚替诺福韦的HIV感染者生活质量及治疗满意度：观察性队列研究的汇总分析 Andrea AntinoriYoshiyuki YokomakuMarta Boffito Pages: 217 - 244 14 Dual Transmission Dynamics of Carbapenem Resistance in Pediatric Oncology: Plasmid-Mediated and Clonal Spread of blaNDM-5 Enterobacterales 儿科肿瘤中碳青霉烯类耐药性的双重传播动态：blaNDM-5肠杆菌科的质粒介导与克隆传播 Deena JalalMaryam LotfiLobna Shalaby Pages: 245 - 263 Part of 1 collection:Digital Features - Infectious Diseases 所属专题集：数字专题 - 传染病 15 Cost-Effectiveness Analysis of Aztreonam–Avibactam Compared with Colistin Plus Meropenem in Treating Metallo-Beta-Lactamase-Producing Enterobacterales Infections in Spain 氨曲南-阿维巴坦与黏菌素联合美罗培南治疗西班牙产金属β-内酰胺酶肠杆菌科感染的成本效果分析 Gerardo AguilarPatricia Ruiz-GarbajosaJulián Torre-Cisneros Pages: 265 - 284 16 Synchronous anal HPV Infection in Patients with HPV-Related Gynaecological Diseases: A Prospective Study 人乳头瘤病毒（HPV）相关妇科疾病患者同步肛部HPV感染：一项前瞻性研究 Michał BrzezińskiMaciej Stukan Pages: 285 - 295 17 Growth in Anaerobic Bottles is an Independent Predictor of Mortality in Pseudomonas aeruginosa Bloodstream Infections 厌氧瓶中生长是铜绿假单胞菌血流感染死亡的独立预测因素 Daniel N. MarcoLaura MorataAlex Soriano Pages: 297 - 311 18 Acute and Long-Term Healthcare Utilization and Expenditures for Serious Bacterial Infections among Newborns in US Hospitals 美国医院新生儿严重细菌感染的急性和长期医疗资源利用及费用 Kristen N. NobleKatharina SchleyDerek Weycker Pages: 313 - 325 19 Impact of Risk Stacking on COVID-19–Related Healthcare Utilization: A Real-World Retrospective Cohort Study 风险叠加对新冠相关医疗资源利用的影响：一项现实回顾性队列研究 Frank R. ErnstLeah McGrathAlejandro Cané Pages: 327 - 343 20 Chest Computed Tomography Patterns Associated with Severity in Adults with Respiratory Syncytial Virus Infection: A Retrospective Cohort Study 成人呼吸道合胞病毒感染严重程度相关的胸部计算机断层扫描模式：一项回顾性队列研究 Marie Le GoffYoussef ZaarourNicolas de Prost Pages: 345 - 363 Case Series（病例系列） 21 Management and Resolution of Hypersensitivity Pneumonitis-Related Events in Japanese Patients Treated with Amikacin Liposome Inhalation Suspension in the CONVERT and INS-312 Clinical Trials 在CONVERT和INS-312临床试验中，接受硫酸阿米卡星脂质体吸入混悬液治疗的日本患者发生过敏性肺炎相关事件的管理与解决 Yoshitaka YamazakiTaku NakagawaNaoki Hasegawa Pages: 365 - 379 Letter（读者来信） 22 A Response to: Letter to the Editor Regarding “The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis” 对《关于“抑郁障碍患者带状疱疹风险：一项德国索赔数据库分析”的来信》的回复 Pavo MarijicJulian WitteChristiane Hermann Pages: 381 - 383 23 Letter to the Editor Regarding“The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis” 致编辑的信：关于“抑郁障碍患者带状疱疹风险：一项德国索赔数据库分析” Kuan-Fu LiaoShih-Wei Lai Pages: 385 - 386 Correction（更正） 24 Correction: Budget Impact Analysis of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) for Recurrent Clostridioides difficile Infection in the United States 更正：美国复发性艰难梭菌感染粪便微生物群孢子活菌brpk（原SER-109）的预算影响分析 Michele WilsonYoav GolanAlpesh N. Amin Pages: 387 - 387 25 Correction: A Response to: Letter to the Editor Regarding “The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis” 更正：对《关于“抑郁障碍患者带状疱疹风险：一项德国索赔数据库分析”的来信》的回复 Pavo MarijicJulian WitteChristiane Hermann Pages: 389 – 389 Infectious Diseases and Therapy Volume 15, Issue 2 感染性疾病与治疗 15卷 2期 https://link.springer.com/journal/40121/volumes-and-issues/15-2 Review（综述） 1 HepatitisA to E in People with HIV: A Virus-Specific Review of Prevention and Treatment HIV感染者中的甲型至戊型肝炎：针对不同病毒的预防和治疗综述 Kuan-Yin LinYi-Chia HuangChien-Ching Hung Pages: 391 - 415 2 The Cefazolin Inoculum Effect: An Underappreciated Factor in MSSA Treatment Strategies 头孢唑林接种物效应：甲氧西林敏感金黄色葡萄球菌治疗策略中一个未被充分重视的因素 Prakhar SrivastavaElizabeth SingletonRazieh Kebriaei Pages: 417 - 441 3 Meningococcal Disease in Older Adults: Challenges in Diagnosis and Management 老年人群中的脑膜炎球菌病：诊断与治疗的挑战 Muhamed-Kheir TahaCatherine Weil-OlivierSaber Yezli Pages: 443 - 459 4 The Future of Antibiotics and Artificial Intelligence: Some Thoughts from Discovery to Bedside 抗生素与人工智能的未来：从发现到临床应用的一些思考 Daniele Roberto GiacobbeAlessandra Agnese GrossiCesar de la Fuente-Nunez Pages: 461 - 475 Original Research（论著） 5 Estimating the Health and Economic Burden of Pneumococcal Diseases Attributable to PCV21 Versus PCV20 or PPSV23 Serotypes Among Adults in Norway 挪威成年人中PCV21与PCV20或PPSV23血清型所致肺炎球菌疾病的健康和经济负担估算 Zinan YiAthar Ali TajikKwame Owusu-Edusei Pages: 477 - 490 6 Seven versus Fourteen Days of Antibiotics for Gram-Negative Bacteremia from a Urinary Tract Source: a Systematic Review and Meta-analysis 尿路感染来源的革兰阴性菌血症抗生素治疗7天与14天的系统综述和荟萃分析 Graciela LunaAndrea RodriguezMichael Sabina Pages: 491 - 505 7 Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Causing Healthcare-Associated Bloodstream Infections in Brazil: Results from A Prospective Countrywide Multicenter Study 巴西医疗保健相关血流感染中耐甲氧西林金黄色葡萄球菌的分子流行病学：一项前瞻性全国多中心研究的结果 Laura C. AntochevisLetícia O. SudbrackAlexandre P. Zavascki Pages: 507 - 525 8 Long-Term Antibody Persistence After Hepatitis A Vaccination in Healthy Toddlers: Insights from Modeling 健康幼儿接种甲型肝炎疫苗后长期抗体持久性：基于模型的见解 Carlos EspulHéctor Horacio CuelloLaurent Coudeville Pages: 527 - 538 9 Prevalence of Respiratory Syncytial Virus in Adult Patients with Respiratory Illnesses in Low to Middle-Income Countries: A Systematic Review and Meta-Analyses 中低收入国家成人呼吸道疾病患者中呼吸道合胞病毒的流行率：一项系统综述和荟萃分析 Digant GuptaAmandeep KaurAdriana Guzman-Holst Pages: 539 - 559 10 Novel Diagnostic Marker Interleukin-33 for Invasive Pulmonary Aspergillosis in Acute-on-Chronic Liver Failure: A Proof-of-Concept Prospective Study 慢加急性肝衰竭合并侵袭性肺曲霉病的新型诊断标志物白细胞介素-33：一项概念验证前瞻性研究 Lanyue HuangMeng ZhangQin Ning Pages: 561 - 576 11 Testing the Feasibility of a Self-Help Intervention That Includes Lymphatic Drainage to Reduce Fatigue-Related Symptoms Among Patients with Long COVID in General Practice: Experiences from Our Randomized Controlled Trial (RCT) 在全科医疗中测试包含淋巴引流以减轻长期新冠患者疲劳相关症状的自助干预措施的可行性：我们的随机对照试验（RCT）经验 Lisa RisteRaymond PerrinAdrian Heald Pages: 577 - 589 12 Comparative Diagnostic Performance of the 36-Minute STANDARD M10 Fast Assay for Molecular Diagnosis of SARS-CoV-2, InfluenzaA and B, and Respiratory Syncytial Virus in Near-Patient Settings 36分钟STANDARD M10快速检测法在床旁检测中对SARS-CoV-2、甲型和乙型流感病毒以及呼吸道合胞病毒的分子诊断性能比较 Alexander DomnichGiada GarzilloGiancarlo Icardi Pages: 591 - 604 13 Clinical Phenotypes of Critically Ill Patients with COVID-19 Infected with Omicron: A Nationwide Prospective Cohort Study 感染奥密克戎的危重症COVID-19患者的临床表型：一项全国性前瞻性队列研究 Etienne AudureauPierre Baythe SEVARVIR investigators Pages: 605 - 628 Brief Report（简报） 14 How do Recent Population-Level RSVpreF Vaccine-Impact Results from the United Kingdom Relate to Previously Reported Vaccine Effectiveness Results? 英国最近公布的RSVpreF疫苗在人群层面的影响结果与之前报告的疫苗有效性结果有何关联？ Negar AliabadiQing LiuElizabeth Begier Pages: 629 - 637 Case Report（病例报告） 15 Continuous Infusion of Aztreonam–Avibactam After High Loading Dose for an Infection Caused by an OXA-48- and NDM-1-Co-producing ST147 Klebsiella pneumoniae 针对OXA-48和NDM-1共产生的ST147型肺炎克雷伯菌感染，采用高负荷剂量后持续输注氨曲南-阿维巴坦 Paul Laffont-LozesFanny VillaRomaric Larcher Pages: 639 - 649 Infectious Diseases and Therapy Volume 15, Issue 3 感染性疾病与治疗 15卷3期 https://link.springer.com/journal/40121/volumes-and-issues/15-3 Commentary（述评） 1 Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease 预防婴儿呼吸道合胞病毒疾病中孕妇接种疫苗的全面健康及社会价值的分类学研究 J. P. SevillaDaria BurnesDavid E. Bloom Pages: 651 - 682 Original Research（论著） 2 Characteristics of Haemophilus influenzae Isolates Responsible for Invasive Infections in Poland in 2018–2023 2018-2023年波兰引起侵袭性感染的流感嗜血杆菌分离株的特征 Marlena KiedrowskaKinga BłaszczykAnna Skoczyńska Pages: 683 - 700 3 Evaluating the Effectiveness of 2024–2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged ≥ 18 years in the United States: An Observational Matched Cohort Study 评估2024-2025年季节性mRNA-1273疫苗对美国≥18岁成年人预防与COVID-19相关住院和就医的效力：一项观察性匹配队列研究 Nevena VicicAlina BogdanovAmanda Wilson Pages: 701 - 714 4 Elevated Plasma GDF-15 Levels Are Associated with Aging, Multimorbidity, and Tobacco Exposure in People with HIV HIV感染者中血浆GDF-15水平升高与衰老、多种合并症及烟草暴露相关 Aida López LópezJacobo Alonso DomínguezCoRIS Cohort Pages: 715 - 731 5 High Burden of Febrile Sub-microscopic Plasmodium Mixed Infections in Central India: A Cross-Sectional Study 印度中部无症状疟原虫混合感染伴发热疾病负担高：一项横断面研究 Nimita DeoraVeena PandeAbhinav Sinha Pages: 733 - 747 6 How Status Quo Bias Shapes Willingness, Uptake, and Adherence to PrEP Among Chinese MSM: A Behavioral Economics Perspective 从行为经济学视角看现状偏见如何影响中国男男性行为者对暴露前预防的意愿、接受度和依从性 Min ZhaoXiang ZhaoLei Zhang Pages: 749 - 767 7 Immunogenicity and Safety of Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Potential Hajj/Umrah Pilgrims Aged≥56 Years: A Phase III, Open-Label Study 四价脑膜炎球菌结合疫苗（MenACYW-TT）在≥56岁潜在朝觐/副朝觐者中的免疫原性和安全性：一项III期、开放标签研究 Ghassan S. DbaiboIsmail BalikMehmet Ceyhan Pages: 769 - 785 Part of 1 collection: Digital Features - Infectious Diseases 所属合集：数字专题 -传染病 8 Clinical Impact of Droplet Digital PCR-Guided Antibiotic Stewardship on Prognosis in Patients with Suspected Bloodstream Infection: A Prospective Observational Study 液滴数字PCR指导的抗生素管理对患者疑似血流感染预后的临床影响：一项前瞻性观察研究 Ziqiang ShaoJingwen ZhuBangchuan Hu Pages: 787 - 807 9 Outpatient RSV Testing Rates Among US Adults with Lower Respiratory Tract Disease, 2017–2024 2017-2024年美国下呼吸道疾病成人患者门诊呼吸道合胞病毒检测率 Katherine K. PerezKashmira DateElizabeth Begier Pages: 809 - 834 10 Role of Cefiderocol in the Treatment of Carbapenem-Resistant Nonfermenting Gram-Negative Bacilli (Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia) Infections: An Expert Statement 头孢地尔在治疗碳青霉烯类耐药非发酵革兰氏阴性杆菌（鲍曼不动杆菌、铜绿假单胞菌和嗜麦芽窄食单胞菌）感染中的作用：专家声明 Alexandre BleibtreuYoussef BennisCoRIS Cohort Pages: 835 - 857 11 IgG4 Neutralization and Sustained Total IgG Fc-Effector Functions Following Repeated SARS-CoV-2 Vaccination with mRNA-1273 重复接种mRNA-1273疫苗后IgG4中和作用及总IgG Fc效应功能的持续存在 Paulina KaplonekHarry BerteraCarole Henry Pages: 859 - 874 12 Rising Burden of Herpes Zoster among General Adults and Increased-Risk Groups in Eastern China, 2015–2021: A Population-Based Cohort Study 2015-2021年中国东部普通成人及高风险人群带状疱疹负担上升：一项基于人群的队列研究 Zhenwei LiShenjia GuChuanxi Fu Pages: 875 - 888 13 Safety and Efficacy of Fecal Microbiota, Live-jslm for Prevention of Recurrent Clostridioides difficile Infection Among Hospitalized Participants in PUNCH CD3-OLS PUNCH CD3-OLS研究中住院患者使用活菌粪便微生物群（Live-jslm）预防复发性艰难梭菌感染的安全性和有效性 Andrew M. SkinnerThomas P. LodiseJordan E. Axelrad Pages: 889 - 901 Letter（读者来信） 14 Letter to the Editor Regarding “Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States” 致编辑的信：关于“美国HIV和乙型肝炎病毒合并感染者启动抗逆转录病毒治疗后发生晚期肝病事件” Keiji Konishi Pages: 903 - 905 15 A Response to: Letter to the Editor Regarding “Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States” 回复：致编辑的信——关于“美国HIV和乙型肝炎病毒合并感染者启动抗逆转录病毒治疗后发生晚期肝病事件” Ching-Yi ChuoWoodie ZachryLi Tao Pages: 907 - 909 16 A Response to: “Letter to the Editor regarding ‘Impact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study'” 回复：致编辑的信——关于“聚丙烯腈衍生滤器连续性肾脏替代治疗对卡泊芬净浓度的影响：一项回顾性研究” Romain ArrestierKeyvan Razazi Pages: 911 - 914 17 Letter to the Editor regarding 'Impact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study' 致编辑的信——关于“聚丙烯腈衍生滤器连续性肾脏替代治疗对卡泊芬净浓度的影响：一项回顾性研究” Julien MassolValentin MauletFrédéric J. Baud Pages: 915 - 919 Infectious Diseases and Therapy Volume 15, Issue 4 感染性疾病与治疗 15卷 4期 https://link.springer.com/journal/40121/volumes-and-issues/15-4 Review（综述） 1 Outpatient Parenteral Antimicrobial Therapy (OPAT) in Italy: A Scoping Review 意大利门诊静脉注射抗菌药物治疗（OPAT）：一项范围综述 Chiara MorealSimone GiulianoCarlo Tascini Pages: 921 - 939 2 Reimagining Phage Therapy for MDR Pathogens: From Biobanks to Health System Integration—A Review 重新构想噬菌体疗法治疗多重耐药病原体：从生物银行到卫生系统整合——综述 Abay A. AyeleWenfeng LiuAbel A. Negash Pages: 941 - 957 3 Navigating the Viral Hepatitis Drug Landscape: New Discoveries and Enduring Challenges. A Narrative Review 探索病毒性肝炎药物领域：新发现与持久挑战。一篇叙述性综述 He-ming SunXing-yu WangYan-hang Gao Pages: 959 - 985 Original Research（论著） 4 Predictive Utility of the Pediatric-EQUAL Scale in Pediatric Candidemia Admitted to PICU Association with Clinical and Microbiological Factors Related Mortality 儿科-EQUAL量表对入住PICU的念珠菌血症患儿的预测效用：与临床和微生物学因素相关死亡率的关联 Muhterem DuyuAyşe Aşık Pages: 987 - 1001 Publisher Correction（出版商更正） 5 Publisher Correction: Predictive Utility of the Pediatric-EQUAL Scale in Pediatric Candidemia Admitted to PICU Association with Clinical and Microbiological Factors Related Mortality 出版商更正：儿科-EQUAL量表对入住PICU的念珠菌血症患儿的预测效用：与临床和微生物学因素相关死亡率的关联 Muhterem DuyuAyşe Aşık Pages: 1003 - 1005 Original Research（论著） 6 A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19 用于从中和抗体滴度预测疗效以建立预防新冠肺炎单克隆抗体免疫桥接的统计免疫保护相关因素模型 Ilker YalcinLeijun HuMark A. Wingertzahn Pages: 1007 - 1017 7 Early Antibiotic Therapy in Sepsis Without Shock: A Multimethod Study of Heterogeneous Treatment Effects in ICU Patients 无休克性脓毒症的早期抗生素治疗：一项针对ICU患者异质性治疗效果的多方法研究 Peng ZhangTongkun ZuoYing Huang Pages: 1019 - 1033 8 Post-marketing Safety Surveillance of 23-Valent Pneumococcal Polysaccharide Vaccine Administered Alone and Concomitantly with Influenza Vaccine in Individuals Aged 2Years and Older in China 中国2岁及以上人群单独接种及与流感疫苗同时接种23价肺炎球菌多糖疫苗的上市后安全监测 Yun-feng ShiLin-hang JuHong-xing Pan Pages: 1035 - 1046 9 Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study 美国预防婴儿呼吸道合胞病毒下呼吸道感染：Nirsevimab和Clesrovimab的成本效益——一项建模研究 Benjamin YarnoffMatthieu BeuveletLeonard R. Krilov Pages: 1047 - 1073 10 Oritavancin in Complicated Bloodstream Infections and Endocarditis in Spain and Italy (ORIBAC Study): A Retrospective Multicenter Observational Study 西班牙和意大利奥利他万星治疗复杂血流感染和心内膜炎（ORIBAC研究）：一项回顾性多中心观察研究 Antonio VenaLaura MezzogoriORIBAC study group Pages: 1075 - 1092 11 Mitigating Vaccine Disparities Through Faith-Based Intervention: A Pre-Post Analysis of Recombinant Zoster Vaccine Knowledge and Acceptance in Socially Vulnerable Racial and Ethnic Minoritized Communities 通过基于信仰的干预措施减轻疫苗差异：对社会弱势的种族和少数民族群体重组带状疱疹疫苗认知和接受度的前后分析 Jacinda C. Abdul-MutakabbirRaheem Abdul-MutakabbirSamuel J. Casey Pages: 1093 - 1114 12 Epidemiological Burden and Hospitalization Trends of Human Metapneumovirus in Spain (2016–2023): A Retrospective Study 西班牙人类偏肺病毒的流行病学负担和住院趋势（2016 - 2023年）：一项回顾性研究 Oscar Brochado-KithRuth Gil-PrietoAngel Gil-de-Miguel Pages: 1115 - 1135 13 Using Real-World Data to Support Claim Expansion of the Cobas SARS-CoV-2 Test in Asymptomatic Testing: Data from the National Football League Occupational Surveillance Program 使用现实数据支持Cobas SARS-CoV-2检测在无症状检测中的适用范围扩大：来自美国国家橄榄球联盟职业监测计划的数据 Baiyu YangErin B. WassermanElodie Baumfeld Andre Pages: 1137 - 1148 Infectious Diseases and Therapy Volume 15, Issue 5 感染性疾病与治疗 15卷 5期 https://link.springer.com/journal/40121/volumes-and-issues/15-5 Review（综述） 1 Efficacy and Safety of Tetracyclines in Bone and Joint Infections: A Literature Review 四环素类药物治疗骨关节感染的有效性和安全性：文献综述 Paul Laffont-LozesRomaric LarcherAlbert Sotto Pages: 1149 - 1174 2 The Ongoing Challenge of Pertussis in Eastern and Northern Europe: Recommendations from the Global Pertussis Initiative 东欧和北欧百日咳持续存在的挑战：全球百日咳倡议的建议 Mine Durusu TanrioverUlrich HeiningerKevin Forsyth Pages: 1175 - 1201 3 Antibiotic Pharmacokinetics and Prostate Penetration in Bacterial Prostatitis: A Systematic Review 细菌性前列腺炎的抗生素药代动力学及前列腺穿透性：系统综述 Rui GeXinwen NianZhuo Wang Pages: 1203 - 1248 4 Treatment for Dientamoeba fragilis: A Systematic Review and Meta-analysis 脆弱双核阿米巴病的治疗：系统综述和荟萃分析 Nadav BaharavMichael ItzkovichDafna Yahav Pages: 1249 - 1262 Original Research（论著） 5 Preparing for Tuberculosis Vaccine M72/AS01E Implementation: A Global Demand Forecast and Key Influential Factors 结核病疫苗M72/AS01E实施准备工作：全球需求预测及关键影响因素 Judith KallenbergDominique MileaAgathe Philippot Pages: 1263 - 1279 Correction（更正） 6 Correction: Preparing for Tuberculosis Vaccine M72/AS01E Implementation: A Global Demand Forecast and Key Influential Factors 更正：结核病疫苗M72/AS01E实施准备工作：全球需求预测及关键影响因素 Judith KallenbergDominique MileaAgathe Philippot Pages: 1281 - 1281 Original Research（论著） 7 Impact of Nirsevimab on Pediatric RSV-Related Lower Respiratory Tract Infections: A Retrospective Pre–Post Observational Study in Tuscany, Italy 尼塞韦单抗对意大利托斯卡纳地区儿童呼吸道合胞病毒相关下呼吸道感染的影响：一项回顾性前后对照观察研究 Francesco NiedduMarta VerzieriMaria Moriondo Pages: 1283 - 1295 8 Antiretroviral Therapy Switching Among People with HIV in the United States is not Uncommon Despite Virologic Suppression: An OPERA Cohort Study 尽管病毒学抑制，美国HIV感染者更换抗逆转录病毒疗法的情况并不少见：OPERA队列研究 Karam MounzerMichael D. OstermanGregory P. Fusco Pages: 1297 - 1314 9 Role of Community Associations in HIV, HBV and HCV Screening and Support for Migrant Populations in France: Results of the DéPAC Study 社区协会在法国移民人群HIV、HBV和HCV筛查及支持中的作用：DéPAC研究结果 Dulce AlfaiateJean-Claude TardyFrançois Durand Pages: 1315 - 1333 Part of 1 collection:Digital Features - Infectious Diseases 所属专题合集：数字专题-传染病 10 Impact of Risk Factor Combinations on Severe COVID-19 Outcomes Among Outpatients 风险因素联合作用对门诊患者严重新冠肺炎预后的影响 Haley J. AppanealVrishali V. LopesAisling R. Caffrey Pages: 1335 - 1351 11 Clinical Outcomes Among Older Adults Hospitalized with Respiratory Syncytial Virus and Influenza Infection: A Retrospective Analysis 老年住院患者呼吸道合胞病毒和流感病毒感染的临床预后：一项回顾性分析 Menucha JurkowiczIli MargalitMichal Mandelboim Pages: 1353 - 1367 12 The Impact and Effectiveness of a Two-Dose Varicella Immunization Program Among School Children: Evidence from Quasi-experimental Analyses 两剂水痘免疫接种计划对学龄儿童的影响和有效性：来自准实验分析的证据 Huiqiao GuXu XieYawen Jiang Pages: 1369 - 1384 13 Lessons Learned: Defining the Right Specifications for Diagnostics in Outbreak Situations 经验教训：疫情情况下确定诊断的正确规范 Markus BeutlerPablo BonvehíAndreas Wieser Pages: 1385 - 1399 14 Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022–2023 2022-2023年INFORM研究结果：英格兰地区普通人群和高危人群中新冠肺炎后严重流感的负担 Wilhelmine MeerausLucy CartyLance Turtle Pages: 1401 - 1424 15 Respiratory Syncytial Virus Immunization Strategies for Older Adults in Gulf Cooperation Council Countries: Expert Consensus and Recommendations 海湾合作委员会国家老年人呼吸道合胞病毒免疫接种策略：专家共识和建议 Nawal AlKaabiMohammed AbukhattabSalah Al Awaidy Pages: 1425 - 1449 16 Prospective Study of Treatment with Ensitrelvir for COVID-19 in Patients Undergoing Hemodialysis (PROTECT-HD) 血液透析患者使用恩赛特韦治疗新冠肺炎的前瞻性研究（PROTECT-HD） Mineaki KitamuraTakahiro TakazonoHiroshi Mukae Pages: 1451 - 1466 17 Diagnostic Performance and Clinical Outcomes of Pertussis in Hospitalized Children in Relation to Available Vaccination Status: A Retrospective Cohort Study 在现有疫苗接种情况下，住院患儿百日咳的诊断性能和临床预后：一项回顾性队列研究 Dominika LachowiczBarbara JastrzębskaEdyta Podsiadły Pages: 1467 - 1477 18 Demonstrating Clinical Performance of the Elecsys Anti-SARS-CoV-2 Anti-Nucleocapsid Immunoassay Using Real-World Data to Support Regulatory Decision-Making in the USA 使用现实数据证明Elecsys抗SARS-CoV-2抗核衣壳免疫检测的临床性能，以支持美国监管决策 Eldad A. HodBaiyu YangElodie Baumfeld Andre Pages: 1479 - 1491 19 Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis 格卡瑞韦/哌仑他韦治疗慢性丙型肝炎病毒感染且伴有合并症或多种合并用药受试者的有效性和安全性：一项综合分析 Curtis CooperShweta A. RainaStanislas Pol Pages: 1493 - 1508 20 Modeling the Public Health Impact of Introducing 4CMenB Vaccination for Infants in the Brazilian National Immunization Program 在巴西国家免疫计划中引入4CMenB疫苗对公共卫生的影响建模 Thatiana PintoZeki KocaataElise Kuylen Pages: 1509 - 1524 21 Multicenter Real-World Outpatient Use of Intravenous Omadacycline 门诊使用静脉注射奥马环素的多中心现实情况 Lucinda J. Van AnglenCathy L. KooKimberly A. Couch Pages: 1525 - 1538 22 Burden of Respiratory Syncytial Virus in Older ADults in Nagasaki, Japan (Nagasaki ROAD): Preliminary Results (April 2024–March 2025) of a Prospective, Multicenter, Epidemiological Study 日本长崎地区老年人呼吸道合胞病毒负担（长崎ROAD）：一项前瞻性、多中心、流行病学研究的初步结果（2024年4月-2025年3月） Takahiro TakazonoNorihito KakuHiroshi Mukae Pages: 1539 - 1564 Brief Report（简报） 23 Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study) 对于病毒学抑制的HIV感染者，从利匹韦林或其他非核苷类逆转录酶抑制剂（NNRTI）为基础的抗逆转录病毒疗法转换为比克替拉韦/恩曲他滨/丙酚替诺福韦的有效性：一项回顾性分析（DRIVE-SWITCH研究） Roberta GagliardiniAlessandro CaioliAndrea Antinori Pages: 1565 - 1575 Infectious Diseases and Therapy Volume 15, Issue 6 感染性疾病与治疗 15卷 6期 https://link.springer.com/journal/40121/volumes-and-issues/15-6 Commentary（述评） 1 Adult RSV Vaccination: What Is the Role of RSV Subgroup in Disease Prevention? 成人RSV疫苗接种：RSV亚群在疾病预防中的作用是什么？ S. Elizabeth WilliamsGiovanni Checcucci LisiElizabeth Begier Pages: 1577 - 1587 Review（综述） 2 Epidemiology of Acute Cystitis or Afebrile Urinary Tract Infection in Adult Men: A Systematic Literature Review 成年男性急性膀胱炎或无热尿路感染的流行病学：一项系统文献综述 Mary E. GeorgiouPriscilla WittkopfFanny S. Mitrani-Gold Pages: 1589 - 1606 3 Non-intravenous Amphotericin B: A Review of Localized Administration Routes 非静脉注射两性霉素B：局部给药途径综述 Francelise Bridi CavassinLaura Fernanda RodriguesMarcello Mihailenko Chaves Magri Pages: 1607 - 1632 4 Infections Caused by Fusobacterium Species: Microbiology, Clinical Syndromes and Management: A Narrative Review Fusobacterium属引起的感染：微生物学、临床综合征及治疗：一篇叙述性综述 Michal ParetGuy KatzenellenbogenDafna Yahav Pages: 1633 - 1647 5 When Culture Results Don’t Tell the Whole Story: A Practical Review of Antibiotics Pitfalls for Clinical Decision-Making 当培养结果不能说明全部问题：临床决策中抗生素陷阱的实用综述 Ahmed M. ShomanAyman A. Radwan Pages: 1649 - 1667 Original Research（论著） 6 Cost-Effectiveness of Alternative Immunization Strategies to Protect Infants Against Respiratory Syncytial Virus in Germany: A Decision Modeling Study 德国保护婴儿免受呼吸道合胞病毒感染的替代免疫策略的成本效益：一项决策模型研究 Caroline LadeErin QuinnAhuva Averin Pages: 1669 - 1687 7 Estimation of Costs Related to the Management of Herpes Zoster and its Complications in Vietnam: A Medical Chart Review 越南带状疱疹及其并发症治疗相关费用估算：一项病历回顾研究 Nurilign AhmedVan M. NguyenHuong T. T. Nguyen Pages: 1689 - 1704 8 Validation of the VIRSTA and VIRSTA+ Scores to Identify Patients with Staphylococcus aureus Bacteremia at Very Low Risk of Infective Endocarditis VIRSTA和VIRSTA+评分验证以识别感染性心内膜炎极低风险的金黄色葡萄球菌菌血症患者 Daniela Malano-BarlettaMiguel Ángel VerdejoAlex Soriano Pages: 1705 - 1718 9 The Shifting Landscape of HIV–Tuberculosis Co-Infection in the MENA Region with a Focus on Saudi Arabia: A Systematic Epidemiological Analysis over Three Decades MENA地区HIV–结核共感染的变化格局：以沙特阿拉伯为重点的三十年系统流行病学分析 Zikria SaleemMasaad Saeed AlmutairiFaris S. Alnezary Pages: 1719 - 1731 10 Comprehensive Analysis of Health Service Utilization for Febrile Illness and Malaria in Malaria-Endemic States in India: LLINs as a Pillar of Control Strategies 印度疟疾流行邦发热疾病和疟疾卫生服务利用的综合分析：长效杀虫蚊帐作为控制策略的支柱 Vani H. ChalageriShrinivasa B. MarinaikAnupkumar R. Anvikar Pages: 1733 - 1746 11 Observational, Post-marketing Surveillance of Safety and Effectiveness of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C 格卡瑞韦/匹布他韦在韩国慢性丙型肝炎患者中的观察性上市后安全性和有效性监测 Jin-Woo LeeSang Hoon AhnJeong Heo Pages: 1747 - 1761 12 Post-Marketing Active Surveillance of Adverse Events Following Quadrivalent Subunit Influenza Vaccine in Healthy Participants Aged≥3 Years in China 中国≥3岁健康人群接种四价亚单位流感疫苗后不良事件的上市后主动监测 Mingwei WeiYu PanHongxing Pan Pages: 1763 - 1778 Systematic Review（系统综述） 13 Point-of-Care Nucleic Acid Amplification Tests for Respiratory Syncytial Virus Detection in Children and Adults: A Systematic Literature Review 用于儿童和成人呼吸道合胞病毒检测的即时核酸扩增检测：一项系统文献综述 Kashmira DateKyle FowlerElizabeth Begier Pages: 1779 - 1799 Correction（勘误） 14 Correction: The Cefazolin Inoculum Effect: An Underappreciated Factor in MSSA Treatment Strategies 勘误：头孢唑林接种效应：MSSA治疗策略中被低估的因素 Prakhar SrivastavaElizabeth SingletonRazieh Kebriaei Pages: 1801 – 1801

100 项与 ACYW135群脑膜炎球菌结合疫苗(赛诺菲) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07AH08	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脑膜炎球菌感染	加拿大	Sanofi Pasteur, Inc.	2020-10-29
侵袭性脑膜炎球菌病	美国	Sanofi Pasteur, Inc.	2020-04-23

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
流行性脑脊髓膜炎	申请上市	欧盟	Sanofi Winthrop Industrie SA	-
脑膜炎	临床2期	美国	Sanofi Pasteur SA	2009-12-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05929651 (CTgov)	临床4期	脑膜炎球菌感染	71	MenACYW conjugate vaccine	顧齋窪艱壓鹽糧鹹範憲 = 願醖觸餘膚夢獵獵鏇襯淵鑰願糧網廠鏇網蓋鏇 (衊鹽憲觸膚鬱遞願襯醖, 網製構壓鑰觸糧鏇夢築 ~ 壓艱衊壓窪觸齋憲繭鹹) 更多	-	2025-09-22
NCT06228586 (CTgov)	临床3期	脑膜炎球菌感染	447	MenACYW Conjugate Vaccine (MenACYW Conjugate Vaccine: 12-23 Months of Age)	艱襯製壓鬱艱窪繭壓繭(醖鬱鹽範積醖鏇糧網餘) = 構積網鑰簾襯廠襯壓遞網獵積餘艱鬱艱鬱遞鹽 (醖鹹糧簾襯觸鬱遞壓鏇, 壓壓窪鑰鬱襯顧築蓋遞 ~ 鹽顧鏇獵選襯齋鑰窪觸) 更多	-	2025-09-17
				MenACYW Conjugate Vaccine (MenACYW Conjugate Vaccine: 24 Months of Age and Above)	艱襯製壓鬱艱窪繭壓繭(醖鬱鹽範積醖鏇糧網餘) = 鹹遞選構糧糧憲夢網襯網獵積餘艱鬱艱鬱遞鹽 (醖鹹糧簾襯觸鬱遞壓鏇, 簾鏇鬱醖願製襯積鏇積 ~ 壓醖齋糧觸鏇鏇繭艱選) 更多
NCT03869866 (MEQ00063, CTgov)	临床3期	脑膜炎球菌感染	290	Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine	積淵鏇構蓋築醖艱廠遞 = 夢築鏇觸壓鬱簾壓獵築網範簾網鹹窪艱鹽鹹襯 (網築網廠顧壓願齋獵艱, 糧顧網鑰壓簾鏇壓廠糧 ~ 膚襯膚糧齋遞網積壓蓋) 更多	-	2025-03-17
NCT04143061 (MET55, CTgov)	临床3期	脑膜炎球菌感染	1,328	MenACYW Conjugate Vaccine (Group 5 + Group 7: MenACYW Conjugate Vaccine)	餘廠齋窪襯餘醖遞製繭 = 壓顧製鹹繭遞構選壓窪鹹遞艱憲願淵鹹齋繭構 (壓窪築艱遞鹹衊餘齋願, 獵齋範淵鹽夢積蓋網餘 ~ 鬱顧餘網醖夢憲鑰齋構) 更多	-	2025-02-03
				Menactra (Group 6 + Group 8: Menactra®)	餘廠齋窪襯餘醖遞製繭 = 憲淵廠構獵簾範壓鑰糧鹹遞艱憲願淵鹹齋繭構 (壓窪築艱遞鹹衊餘齋願, 構鹹製淵淵鬱淵積鑰廠 ~ 簾蓋範廠餘窪築蓋顧選) 更多
NCT03547271 (CTgov)	临床3期	脑膜炎球菌感染	1,660	Pneumococcal vaccine (10-valent)+MenACYW conjugate vaccine+DTaP-IPV-HB-Hib vaccine+MMR vaccine (Group 1: MenACYW)	淵窪壓簾鹽糧鹽廠膚繭(膚範餘築製襯窪簾蓋選) = 網壓膚襯壓獵遞願範糧鏇鏇膚壓壓淵淵窪鹹觸 (衊鹹觸夢鬱壓鹽憲築鏇, 廠壓鑰餘製膚觸憲餘醖 ~ 鹽鹹廠繭網夢網觸鹽鬱) 更多	-	2025-01-22
				Pneumococcal vaccine (10-valent)+DTaP-IPV-HB-Hib vaccine+Meningococcal group A, C, W-135, and Y conjugate vaccine+MMR vaccine (Group 2: Nimenrix)	淵窪壓簾鹽糧鹽廠膚繭(膚範餘築製襯窪簾蓋選) = 夢餘鏇憲構艱積製鏇艱鏇鏇膚壓壓淵淵窪鹹觸 (衊鹹觸夢鬱壓鹽憲築鏇, 窪衊衊窪簾構襯構構積 ~ 築顧鏇廠蓋淵觸範鏇願) 更多
NCT03537508 (CTgov)	临床3期	脑膜炎球菌感染	2,627	MenACYW Conjugate Vaccine (Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination))	艱窪範廠衊願鬱壓夢憲 = 範憲壓齋鏇鏇獵糧鏇獵顧鏇簾網鬱鹽觸製選餘 (鹽夢顧餘製鑰夢齋襯窪, 獵餘齋糧餘製繭膚窪憲 ~ 蓋淵膚獵獵夢願鹹鏇獵) 更多	-	2024-10-15
				MENVEO (Group 2a: MENVEO (Post 12-month Vaccination))	艱窪範廠衊願鬱壓夢憲 = 製鬱積製積齋廠鏇襯醖顧鏇簾網鬱鹽觸製選餘 (鹽夢顧餘製鑰夢齋襯窪, 壓鹹衊糧糧艱鬱鏇艱蓋 ~ 鬱齋廠鹽繭構範艱鬱夢) 更多
NCT03691610 (CTgov)	临床3期	脑膜炎球菌感染	950	MenACYW conjugate vaccine (Infants: Group 1)	顧淵築鬱選蓋顧壓餘憲 = 鬱鏇鏇窪製淵構築鹽構鑰鹹夢簾顧糧遞餘齋選 (製製繭夢繭壓襯簾選選, 憲願構夢窪積壓願廠築 ~ 糧願簾鑰齋夢廠獵積選) 更多	-	2024-06-25
				MENVEO (Infants: Group 2)	顧淵築鬱選蓋顧壓餘憲 = 壓壓醖鹽築範憲獵淵選鑰鹹夢簾顧糧遞餘齋選 (製製繭夢繭壓襯簾選選, 醖範範繭醖顧顧鏇襯遞 ~ 繭醖觸積鏇憲築遞製願) 更多
NCT03632720 (CTgov)	临床3期	脑膜炎球菌感染	788	Meningococcal group B vaccine+Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine+Human rotavirus RIX4414 strain vaccine+Pneumococcal 13-valent polysaccharide conjugate vaccine (Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months))	餘衊鹽願遞襯鑰築衊憲 = 齋顧顧遞鏇觸窪餘網築憲製廠鬱積鏇願願夢壓 (糧鹽選觸醖餘壓製蓋鏇, 顧餘鏇範糧鬱簾網廠願 ~ 鹹艱顧獵構艱糧糧遞鏇) 更多	-	2023-11-07
				Meningococcal group B vaccine+Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine+Human rotavirus RIX4414 strain vaccine+Pneumococcal 13-valent polysaccharide conjugate vaccine (Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months))	餘衊鹽願遞襯鑰築衊憲 = 醖製廠選鹽築鹹網製蓋憲製廠鬱積鏇願願夢壓 (糧鹽選觸醖餘壓製蓋鏇, 鏇餘淵網壓醖選衊鏇膚 ~ 築遞構齋顧膚鬱範夢衊) 更多
NCT03630705 (MET33, CTgov)	临床3期	脑膜炎球菌感染	525	Meningococcal Polysaccharide (Serogroups A, C, Y, and W)+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine+Pneumococcal 13-valent Conjugate Vaccine+Rotavirus Vaccine, Live, Pentavalent (Group 1: MenACYW Conjugate Vaccine (Mexico))	蓋觸鹽鬱願餘製膚積鏇 = 醖繭築鏇鹹夢蓋繭壓構簾餘窪積構艱窪網憲願 (鏇顧製醖窪獵選鬱築糧, 製鏇構窪積餘淵膚積選 ~ 壓製夢遞遞膚願窪鑰醖) 更多	-	2023-10-19
				Meningococcal Polysaccharide (Serogroups A, C, Y, and W)+Measles, Mumps, and Rubella Virus Vaccine Live+Hepatitis B Vaccine+Haemophilus influenza type b Conjugate Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Group 3: MenACYW Conjugate Vaccine (Russian Federation))	淵積鑰範鏇鹽鑰獵憲繭 = 選醖淵構構顧醖廠鏇蓋遞鹹範願選醖選憲糧鬱 (壓膚鏇齋窪廠選選齋廠, 艱衊廠襯願衊遞鏇構構 ~ 製淵積觸獵構鑰蓋鬱廠) 更多
NCT03673462 (MET41, CTgov)	临床3期	脑膜炎球菌感染	2,797	Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)+Hepatitis B Vaccine+Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine+Varicella Virus Vaccine+Rotavirus Vaccine+Pneumococcal 13-valent Conjugate Vaccine+Measles, Mumps, and Rubella Virus Vaccine (Group 1: MenACYW Conjugate Vaccine)	積膚鹽鹽鹹範鹽選衊願 = 襯鏇顧膚遞膚壓繭獵築繭積憲獵製獵觸蓋淵蓋 (築願鏇鑰網顧膚積鏇鑰, 鬱顧醖觸鹽餘膚窪蓋糧 ~ 憲襯襯醖廠憲夢鑰艱遞) 更多	-	2023-10-05
				Hepatitis B Vaccine+Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine+Varicella Virus Vaccine+Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)+Rotavirus Vaccine+Pneumococcal 13-valent Conjugate Vaccine+Measles, Mumps, and Rubella Virus Vaccine (Group 2: MENVEO®)	積膚鹽鹽鹹範鹽選衊願 = 網壓鑰壓鏇窪遞廠鹹餘繭積憲獵製獵觸蓋淵蓋 (築願鏇鑰網顧膚積鏇鑰, 廠餘糧醖築繭顧築廠積 ~ 繭鹹窪廠築網簾窪艱鑰) 更多